New diabetes pill tested in chinese patients – early safety results expected
NCT ID NCT07073170
First seen Nov 19, 2025 · Last updated May 14, 2026 · Updated 30 times
Summary
This early-stage study tested a new daily oral drug, LY3549492, in 36 Chinese adults with type 2 diabetes. The main goal was to check safety and how the drug moves through the body. Participants took the pill or a placebo for several weeks, and the study lasted about 18 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
Dongcheng District, 100009, China
-
Peking University People's Hospital
Beijing, 100033, China
-
West China Hospital of Sichuan University
Chengdu, 610041, China
Conditions
Explore the condition pages connected to this study.